THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
Osteoporosis and osteoporosis-related fracture are important considerations in older patients; however, osteoporosis in men is often underrecognized and undertreated. At the time of this study, it was ...
As people age, the risk of fracturing a bone – whether it’s a hip, a wrist, vertebrae, an ankle or toe, climbs steadily. For women and men who live after a cancer diagnosis, the risk of breaking bone ...
REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...
Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...
Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...
PROLIA (denosumab) 60mg subcutaneous injection by Amgen Amgen announced results from a 7-year, single-arm, open-label extension of the 3-year randomized, double-blind, placebo-controlled, multi-center ...
Meanwhile, Prolia scored in long-term results from an extended trial. Post-menopausal women treated with Prolia for up to 8 years saw their bone mineral density increase by 16.8% on average in the ...
Continued treatment with the osteoporosis drug denosumab (Prolia) was tied to a lower risk of developing diabetes in a Taiwanese cohort study. In a propensity score-matched analysis, adherence to ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Amgen Inc. is conducting a Phase 4 ...
THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback